Literature DB >> 9581223

The cholinergic hypothesis of neuropsychiatric symptoms in Alzheimer's disease.

J L Cummings1, C Back.   

Abstract

A variety of neuropsychiatric symptoms occur in Alzheimer's disease (AD) including agitation, psychosis, depression, apathy, disinhibition, anxiety, purposeless behavior, and disorders of sleep and appetite. Neuropsychiatric symptoms have been related to cholinergic deficiency and improve after treatment with cholinomimetic agents. Cholinergic drugs are unique among psychotropic agents in exerting disease-specific and broad-spectrum effects. These observations provide the basis for the cholinergic hypothesis of the neuropsychiatric symptoms of AD, suggesting that the cholinergic deficit of AD contributes to the neuropsychiatric symptoms of AD and that cholinomimetic therapy ameliorates the behavioral disturbances accompanying AD.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9581223     DOI: 10.1097/00019442-199821001-00009

Source DB:  PubMed          Journal:  Am J Geriatr Psychiatry        ISSN: 1064-7481            Impact factor:   4.105


  46 in total

Review 1.  Cholinergic therapy for neuropsychiatric symptoms in neurologic disorders.

Authors:  D I Kaufer
Journal:  Curr Psychiatry Rep       Date:  1999-10       Impact factor: 5.285

Review 2.  Clinical and economic factors in the treatment of behavioural and psychological symptoms of dementia.

Authors:  M E Hemels; K L Lanctôt; M Iskedjian; T R Einarson
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

3.  The role of the cholinergic system of the sensorimotor cortex of the rat brain in controlling different types of movement.

Authors:  I A Zhuravin; N M Dubrovskaya
Journal:  Neurosci Behav Physiol       Date:  2001 Mar-Apr

4.  Behavioral disturbance in dementia.

Authors:  Abhilash K Desai; Lori Schwartz; George T Grossberg
Journal:  Curr Psychiatry Rep       Date:  2012-08       Impact factor: 5.285

5.  The future of pharmacotherapy for schizophrenia.

Authors:  John M Kane; Anil Malhotra
Journal:  World Psychiatry       Date:  2003-06       Impact factor: 49.548

6.  Methodological issues in the non pharmacological treatment of BPSD in nursing home--the TNM study.

Authors:  E Leone; A Deudon; N Maubourguet; X Gervais; P H Robert
Journal:  J Nutr Health Aging       Date:  2009-03       Impact factor: 4.075

7.  Genetic variation in the alpha 7 nicotinic acetylcholine receptor is associated with delusional symptoms in Alzheimer's disease.

Authors:  Robyn Carson; David Craig; Dominic Hart; Stephen Todd; Bernadette McGuinness; Janet A Johnston; Francis A O'Neill; Craig W Ritchie; A Peter Passmore
Journal:  Neuromolecular Med       Date:  2008-08-12       Impact factor: 3.843

8.  Current and future treatments for Alzheimer's disease.

Authors:  Konstantina G Yiannopoulou; Sokratis G Papageorgiou
Journal:  Ther Adv Neurol Disord       Date:  2013-01       Impact factor: 6.570

9.  Conformational analysis and parallel QM/MM X-ray refinement of protein bound anti-Alzheimer drug donepezil.

Authors:  Zheng Fu; Xue Li; Yipu Miao; Kenneth M Merz
Journal:  J Chem Theory Comput       Date:  2013-02-18       Impact factor: 6.006

Review 10.  Potential for Stem Cells Therapy in Alzheimer's Disease: Do Neurotrophic Factors Play Critical Role?

Authors:  Parul Bali; Debomoy K Lahiri; Avijit Banik; Bimla Nehru; Akshay Anand
Journal:  Curr Alzheimer Res       Date:  2017       Impact factor: 3.498

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.